You are here

Article Text

Article menu
Download PDFPDF
Letter
Anti-saccharomyces cerevisiae antibodies (ASCA) in coeliac disease
  1. A Granito,
  2. L Muratori,
  3. P Muratori,
  4. M Guidi,
  5. M Lenzi,
  6. F B Bianchi,
  7. U Volta
  1. Department of Internal Medicine, Cardioangiology, Hepatology, Alma Mater Studiorum-University of Bologna, Bologna, Italy
  1. Correspondence to:
    Dr A Granito
    Department of Internal Medicine, Cardioangiology, Hepatology, Alma Mater Studiorum-University of Bologna, Policlinico S Orsola-Malpighi, via Massarenti 9, 40138 Bologna, Italy; gralex{at}libero.it

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the paper by Israeli and colleagues (Gut 2005;54:1232–6) assessing the presence of anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) before the occurrence of overt clinical manifestations in patients with Crohn’s disease (CD) and ulcerative colitis (UC). They found that ASCA were present in 31% of CD patients before clinical diagnosis (but not in UC patients or controls), and that pANCA were detectable in two (25%) of eight UC patients before clinical manifestations but not in 24 matched controls. These observations led the authors …

    View Full Text

    Footnotes

    • Conflict of interest: None declared.